# RheumApp: Integrating Patient-Reported Outcomes into Routine Care

Clinical Need

Rheumatology, like many sub-specialties, is experiencing a demand-supply mismatch, with too few clinicians to serve patient demand.

Providing care to patients at the appropriate time based on patient-reported outcomes (PROs) can improve efficiency, appointment availability, and patient satisfaction.

Our Innovative Approach

RheumApp is a mobile health app that has been developed over 6 years through user-centered design with patients and clinicians.

RheumApp allows patients to report symptoms periodically *via* brief, validated questionnaires.

RheumApp is integrated into the clinical workflow through the electronic health record.

RheumApp helps clinicians use PRO data by applying logic-driven notifications when postponing a visit would be permissible or an early visit should be considered.

Results

Multiple studies demonstrate 60-70% patient adherence with RheumApp.

Over a 1-year study, RheumApp suggested delaying a visit for 86% of patients with rheumatoid arthritis.

83% of patients would suggest that other patients use RheumApp.

Over 75% of academic rheumatologists find RheumApp useful.

Commercial Potential

Addressable market estimated at $350M today, with $10B total available market by 2029.

RheumApp has received $200K from MGB Ignite to validate its commercial potential.

The largest US community rheumatology practice is piloting the app starting this year.

The RheumApp IP has been licensed to GreenCape Health, founded in 2024.

GreenCape is seeking $3M Series A funding.

MGB Innovation Contact
Gandhy Pierre-Louis
gpierre-louis1@mgb.org

Dan Solomon, MD, MPH
Liang Distinguished Chair, Professor of Medicine; Rheumatology, Brigham and Women's Hospital; Harvard Medical School
dsolomon@bwh.harvard.edu